IDH3A and glioblastoma: Chemotherapy drug screens demonstrated that expected TMZ responses were observed for Isocitrate dehydrogenase (<i>IDH</i>) mutant diffuse gliomas while drug response was variable for <i>IDH</i> wildtype GBM PTCs.